Program
Dronedarone
Also written as “Dabigatran etexilate plus dronedarone”, “Dronedarone (SR33589)” and “Dronedarone Hydrochloride Tablets”.
Its studies are mostly in Atrial Fibrillation · Heart Failure, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 140 open or running | phase 4since Dec 2, 2009 | Sep 13, 2005 | none ahead |
| Lunan Pharmaceutical Group | 20 open or running | no phasesince Jan 27, 2026 | Jan 27, 2026 | none ahead |
| Boehringer Ingelheim | 10 open or running | phase 1since Feb 28, 2011 | Feb 28, 2011 | none ahead |
| Gilead Sciences | 10 open or running | phase 2since Jan 18, 2012 | Jan 18, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First study: phase 3 study in Atrial FibrillationNew to SanofiSanofi · NCT00174785 · 4,628 enrolled · United States, Argentina, Australia and more
- Nov 25, 20052 phase 3 studies in Atrial FibrillationSanofi · NCT00259428, NCT00259376
- Jun 20, 2007Phase 3 study in Atrial FibrillationSanofi · NCT00489736 · 504 enrolled · United States, Argentina, Australia and more
- Jun 12, 20082 phase 3 studiesSanofi · NCT00697086, NCT00696631
- Dec 2, 2009Phase 4 study in Atrial FibrillationSanofi · NCT01026090 · 292 enrolled · Canada
- Jan 12, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01047566 · 183 enrolled · Netherlands
- May 28, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01135017 · 112 enrolled · United States
- Jun 8, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01140581 · 402 enrolled · Australia, Austria, Estonia and more
- Jun 22, 2010Phase 3 study in Atrial FibrillationSanofi · NCT01151137 · 3,236 enrolled · United States, Argentina, Australia and more
- Sep 9, 20102 phase 4 studies in Atrial FibrillationSanofi · NCT01199081, NCT01198873
- Sep 30, 2010Phase 2 study in Atrial FibrillationSanofi · NCT01213368 · 181 enrolled · Japan
- Feb 28, 2011Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT01306162 · 36 enrolled · Germany
- Jan 18, 2012Gilead Sciences's first study: phase 2 study in Atrial FibrillationNew to Gilead SciencesGilead Sciences · NCT01522651 · 134 enrolled · United States, Germany, Israel and more
- Jan 27, 2026Lunan Pharmaceutical Group's first studies: 2 no phase studies in Atrial FibrillationNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07396519, NCT07396506
TargetBeta
“Voltage-gated L-type calcium channel blocker; Sodium channel alpha subunit blocker; Inward rectifier potassium channel 2 blocker; Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07396519Atrial Fibrillation · China | – | Completed | Lunan Pharmaceutical Group | Dec 7, 2022 | 48 |
| NCT07396506Atrial Fibrillation · China | – | Completed | Lunan Pharmaceutical Group | Jul 10, 2023 | 51 |
| NCT01522651Atrial Fibrillation · United States, Germany, Israel and more | 2 | Completed | Gilead Sciences | Mar 10, 2014 | 134 |
| NCT01306162Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2011 | 36 |
| NCT01213368Atrial Fibrillation · Japan | 2 | Completed | Sanofi | Apr 2011 | 181 |
| NCT01199081Atrial Fibrillation · Colombia, Czech Republic, Denmark and more | 4 | Completed | Sanofi | Apr 2012 | 154 |
| NCT01198873Atrial Fibrillation · United States, Canada | 4 | Terminated | Sanofi | Jan 2012 | 76 |
| NCT01151137Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | Sep 2011 | 3,236 |
| NCT01140581Atrial Fibrillation · Australia, Austria, Estonia and more | 4 | Completed | Sanofi | Dec 2011 | 402 |
| NCT01135017Atrial Fibrillation · United States | 4 | Terminated | Sanofi | Feb 2012 | 112 |
| NCT01047566Atrial Fibrillation · Netherlands | 4 | Completed | Sanofi | Sep 2011 | 183 |
| NCT01026090Atrial Fibrillation · Canada | 4 | Terminated | Sanofi | Dec 2011 | 292 |
| NCT00697086Atrial Fibrillation · Belgium, Czech Republic, France and more | 3 | Completed | Sanofi | Jun 2004 | 174 |
| NCT00696631Heart Failure · Denmark, Hungary, Netherlands and more | 3 | Terminated | Sanofi | Jan 2003 | 653 |
| NCT00489736Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Oct 2008 | 504 |
| NCT00259428Atrial Fibrillation · Belgium, Czech Republic, Denmark and more | 3 | Completed | Sanofi | Aug 2003 | 615 |
| NCT00259376Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Sep 2003 | 629 |
| NCT00174785Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Mar 2008 | 4,628 |
How it is read
Names in the registry
- “Dronedarone”, 7 entries
- “Dabigatran etexilate plus dronedarone”, 4 entries
- “Dronedarone (SR33589)”, 4 entries
- “Dronedarone Hydrochloride Tablets”, 2 entries
- “dronedarone (SR33589)”, 2 entries
Conditions, from the studies’ own filings
- Atrial Fibrillation, 16 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.